Ratings by Citi (Eric Joseph)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/16/2026 | BridgeBio Pharma | BBIO | Maintain | Neutral (N/A) |
|
Details | ||
| 7/16/2026 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Buy (N/A) |
|
Details | ||
| 7/9/2026 | Ionis Pharmaceuticals | IONS | Maintain | Buy (N/A) |
|
Details | ||
| 6/9/2026 | PTC Therapeutics | PTCT | Upgrade | Buy (Neutral) |
70.87 (78.59) |
10.89% | Details | |
| 5/18/2026 | Cytokinetics | CYTK | New Coverage | Buy (N/A) |
75.85 (80.18) |
5.71% | Details | |
| 5/18/2026 | Ionis Pharmaceuticals | IONS | New Coverage | Buy (N/A) |
74.23 (54.39) |
-26.73% | Details | |
| 5/18/2026 | BridgeBio Pharma | BBIO | New Coverage | Neutral (N/A) |
66.13 (81.38) |
23.06% | Details | |
| 5/18/2026 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Buy (N/A) |
51.81 (59.59) |
15.02% | Details | |
| 5/18/2026 | Ascendis Pharma | ASND | New Coverage | Buy (N/A) |
240.50 (261.00) |
8.52% | Details | |
| 5/18/2026 | Alnylam Pharmaceuticals | ALNY | New Coverage | Buy (N/A) |
286.98 (267.47) |
-6.8% | Details |
